PLUR News & Events

Pluri announced that an entity beneficially owned by Alejandro Weinstein, chairman of the board and one of the company's largest shareholders, has entered into a securities purchase agreement with Pluri for an additional $2.5M investment in the company at a 30% premium to the market price on March 24. This additional investment follows Weinstein's prior $2.5M investment announced in connection with his appointment as chairman of the board. The securities purchase agreement relates to a private placement offering consisting of: 625,000 common shares, par value $0.00001 per share of the company, and warrants to purchase up to 625,000 common shares of the company. The combined purchase price for each common share and common warrant is $4.00. The warrants are exercisable immediately upon closing of the transaction at an exercise price of $4.25 per share and will be exercisable until the expiration of the eighteen-month anniversary of the closing of the transaction. The gross proceeds to the company from this transaction are expected to be approximately $2.5M. Pluri intends to use the proceeds from the private placement for general working capital and general corporate purposes.

Pluri announces that the China National Intellectual Property Administration, CNIPA, has granted Pluri Biotech, a wholly owned subsidiary of Pluri, a patent covering its proprietary 3D immune cell expansion and activation technology. The patent, titled "System and Methods for Immune Cells Expansion and Activation in Large Scale," expands Pluri's global intellectual property portfolio, including granted patents in the United States and additional granted patents in Japan, Korea, Australia and Israel. The expanded portfolio supports the Company's strategy to pursue global collaboration and licensing agreements for immune cell therapy products built on Pluri's automated, large-scale manufacturing platform.

Pluri announced the completion of the first phase of its program with Resbiomed Technologies OOD, a European biotechnology company developing extracellular-matrix-based biomaterials and biologics for regenerative medicine. The program is being executed through Pluri's contract development and manufacturing division, PluriCDMO. Under the program, Pluri is applying its proprietary placenta-based technologies and advanced bioprocessing expertise to support Resbiomed in establishing protocols for tissue extraction, separation and processing designed to preserve, concentrate and enhance endogenous collagen components and yield high-quality biological materials for diverse regenerative-medicine applications.

Pluri announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell. Under the ongoing collaboration Remedy Cell's personnel, along with Pluri's Contract Development and Manufacturing Organization division, have successfully completed the full implementation of Remedy Cell's proprietary manufacturing process into Pluri's Good Manufacturing Practice, GMP, facility, conducted GMP training and qualification for the Remedy Cell manufacturing team, executed engineering runs to confirm process robustness and scalability, and manufactured several clinical-grade batches of Remedy Cell's lead candidate. These batches are intended for use in Remedy Cell's initial Phase 1b clinical trial, representing a major step in its clinical development